- Regulus Therapeutics (NASDAQ:RGLS): Q2 EPS of -$0.20 misses by $0.06.
- Revenue of $4.76M beats by $1.32M. (PR)
Regulus Therapeutics misses by $0.06, beats on revenues
Recommended For You
More Trending News
About RGLS Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
RGLS | - | - |
Regulus Therapeutics Inc. |